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Placenta accreta is a severe pregnancy complication and is currently the most common indication for peripartum hysterectomy.
It is becoming an increasingly common complication mainly due to the increasing rate of cesarean delivery. Main risk factor
for placenta accreta is a previous cesarean delivery particularly when accompanied with a coexisting placenta previa. Antenatal
diagnosis seems to be a key factor in optimizing maternal outcome. Diagnosis can be achieved by ultrasound in the majority of
cases. Women with placenta accreta are usually delivered by a cesarean section. In order to avoid an emergency cesarean and to
minimize complications of prematurity it is acceptable to schedule cesarean at 34 to 35 weeks. A multidisciplinary team approach
and delivery at a center with adequate resources, including those for massive transfusion are both essential to reduce neonatal and
maternal morbidity and mortality. The optimal management after delivery of the neonate is vague since randomized controlled
trials and large cohort studies are lacking. Cesarean hysterectomy is probably the preferable treatment. In carefully selected cases,
whenfertilityisdesired,conservativemanagementmaybeconsideredwithcaution.Thecurrentreviewdiscussestheepidemiology,
predisposing factors, pathogenesis, diagnostic methods, clinical implications and management options of this condition.
1.Introduction
Placenta accreta occurs when the chorionic villi invade the
myometrium abnormally. It is divided into three grades
based on histopathology: placenta accreta where the chori-
onic villi are in contact with the myometrium, placenta
increta where the chorionic villi invade the myometrium,
and placenta percreta where the chorionic villi penetrate the
uterine serosa [1].
Placenta accreta is considered a severe pregnancy com-
plication that may be associated with massive and potentially
life-threatening intrapartum and postpartum hemorrhage
[2]. It has become the leading cause of emergency hysterec-
tomy [3]. Maternal morbidity had been reported to occur in
upto60%andmortalityinupto7%ofwomenwithplacenta
accreta. In addition, the incidence of perinatal complications
is also increased mainly due to preterm birth and small for
gestational age fetuses [4–7].
Once a rare occurrence, placenta accreta is becoming
an increasingly common complication of pregnancy, mainly
due to the increasing rate of cesarean delivery over the past
50 years [8]. In view of the fact that the indications for
cesarean delivery seem to be steadily expanding, including
cesarean delivery on maternal request, the incidence of
placenta accreta is likely to continue to increase [9]. Wu
et al. reported an incidence of 1:533 births for the period
from 1982 to 2002, much greater than previous reports
ranging from 1:4027 to 1:2510 births in the 1970s to
1980s, suggesting that this increase is mainly the result of the
increasing rate of cesarean delivery [10]. Several risk factors
for placenta accreta have been reported, including a previous
cesarean delivery particularly when accompanied with a
coexisting placenta previa. Increasing numbers of prior
cesarean deliveries exponentially increase the risk of placenta
accreta [10–14]. The exact pathogenesis of placenta accreta
is unknown. A proposed hypothesis includes a maldevel-
opment of decidua, excessive trophoblastic invasion, or a
combination of both [15]. Defective decidualization, abnor-
mal maternal vascular remodeling, excessive trophoblastic
invasion, or combinations thereof are considered to be the2 Obstetrics and Gynecology International
consequences of previous instrumentation [16]. Due to
the high morbidity associated with this condition, accurate
preoperative diagnosis of placenta accreta plays a crucial role
inthemanagementofthesesituations.Antenatalsonography
is used to support the diagnosis and guide clinical manage-
ment leading probably to favorable outcomes [17]. It has
long been accepted that the deﬁnitive treatment of placenta
accreta is hysterectomy [18, 19]. Conservative options which
include leaving all or part of the placenta in situ when
fertility preservation is desired had also been suggested
[20, 21]. Several adjuvant techniques have been proposed
alongside surgery. These included methotrexate treatment
and/orplacementofpreoperativeinternaliliacarteryballoon
cathetersforocclusionand/orarterialembolizationtoreduce
intraoperative blood loss and transfusion requirements [1].
2. Epidemiology
Once a rare occurrence, placenta accreta is becoming an
increasingly common complication of pregnancy, likely
related to the increasing rate of cesarean delivery over the
lastﬁvedecades[8].Placentaaccretaoccursinapproximately
1:1000 deliveries with a reported range from 0.04% rising
up to 0.9% [10, 11, 22]. Diﬀerences in deﬁnition and study
population may account for this wide range. The bladder is
the most frequently involved extrauterine organ when there
is a placenta percreta. Placenta percreta that invades the
urinary bladder is associated with a substantial morbidity
and mortality [23].
The median maternal age is around 34 years and the
median parity is 2.5. The risk of developing placenta accreta
increases with the number of previous cesarean deliveries.
These range from 2% among women with a placenta previa
only to 39–60% among women with accompanied two or
morepriorcesareandeliveries.Upto88%ofthewomenhave
concomitant placenta previa [11, 24]. Risk factors other than
a previous cesarean include submucous myoma, previous
curettage, Asherman’s syndrome, advanced maternal age,
grandmultiparity, smoking, and chronic hypertension [14].
In addition, Alanis et al. reviewed 72 cases of placenta
accreta that were treated conservatively. Among 15% of
women who had a subsequent pregnancy, 18% developed a
repeated placenta accreta [25], so that prior placenta accreta
is probably a major risk factor as well.
3. Pathogenesis
The exact pathogenesis of placenta accreta is unknown. Gen-
erally, placenta accreta has been diagnosed on hysterectomy
specimens when an area of accretion showed chorionic villi
in direct contact with the myometrium and an absence of
decidua [16, 26]. This ﬁnding may be focal in some cases
while the decidua is present in areas adjacent to the foci of
accreta. This decidual maldevelopment in placenta accreta is
usually associated with previous instrumentation as in the
case of prior cesarean sections or uterine curettages [27].
A proposed hypothesis includes a maldevelopment of
decidua, excessive trophoblastic invasion, or a combination
of both. Tseng and Chou hypothesized that the abnormal
expression of growth, angiogenesis, and invasion-related
factors in the trophoblast populations are the main factors
responsible for the occurrence of placenta accreta [27].
Additionally, Cohen et al. reported that the cytotrophoblast
secretes factors that favor invasion, whereas decidua seems
not to have a major role in regulating cytotrophoblast
invasion in vitro [28]. On the contrary Earl et al. reported
that the immunophenotype of extravillous trophoblastic
populations in placenta accreta is identical to that seen in
normal placenta, suggesting that it is unlikely that overactive
trophoblastic invasion plays a major role in the pathogenesis
of placenta accreta, and the absence of decidua is of greater
importance in the pathogenesis [29]. Data from Tantbirojn
et al. explained invasion of larger vessels in the outer
myometrium and near the serosa to be determined by access
rather than a preexisting defect in trophoblastic growth that
would produce uncontrolled invasion through the entire
depth of the myometrium in cases of accreta [16]. They
propose that increta and percreta more likely arise due to
dehiscence of a scar, which gives cells from the trophoblast
column better access to large outer myometrial vessels [16].
Garmi et al. showed, in vitro, that an induced sharp
decidual incision, imitating the in vivo process, that is,
cesarean section, increased signiﬁcantly the invasion poten-
tial of the trophoblastic cells. Additionally complete reap-
proximationoftheincisededgesofthedeciduainvitromade
the incised decidua to behave similarly to intact decidua
while restricting once again the extent of the invasiveness.
Using the same cohort of trophoblast cells, while changing
only the decidual anatomic characteristics’, the invasion
potential of trophoblastic cells in vitro changed accordingly
emphasizing the role of decidua on the invasion potential
[15].
4.Diagnosis
Placenta accreta should be suspected in women who have
both a placenta previa, particularly anterior, and a history of
cesarean or other uterine surgery. The most important factor
aﬀecting outcome is prenatal diagnosis of this condition.
It gives the opportunity to make a delivery plan that
properly anticipates the expected blood loss and other
potential complications of delivery. In addition, it gives
the opportunity for electively timing the procedure since
prevention of complications ideally requires the presence of
a multidisciplinary surgical team.
Antenatal ultrasound is the technique of choice used
to establish the diagnosis and guide clinical management
[17]. Signs of accretion may be seen as early as in the ﬁrst
trimester. Comstock retrospectively reviewed the ultrasound
examinations performed up to 10 gestational weeks among
women later proven to have placenta accreta on pathological
examination. All had low-lying gestational sacs which are
clearly attached to the uterine scar. The myometrium was
thin in the area of the scar to which the sac was attached
compared to normal early gestational sacs [30].
Though the predictive value of ﬁrst trimester ultrasound
for this diagnosis remains unknown, since most reports are
based on isolated case reports, still, women with signs ofObstetrics and Gynecology International 3
accretion in the ﬁrst trimester should undergo follow-up
imaginglaterinthesecondandthirdtrimesterwithattention
to the potential presence of placenta accreta [31].
Second and third trimester gray-scale sonographic
characteristics include loss of continuity of the uterine
wall, multiple vascular lacunae (irregular vascular spaces)
within placenta, giving “Swiss cheese” appearance adjacent
to the placental implantation site, lack of a hypoechoic
border (myometrial zone) between the placenta and the
myometrium, bulging of the placental/myometrial site into
the bladder, and increased vasculature evident on color
Doppler sonography. Wong et al. reported that using a com-
posite scoring system of 6 sonographic ﬁndings performed
with gray-scale and Doppler sonography had 89% sensitivity
and98%speciﬁcityforthediagnosisofplacentaaccreta[32].
Shih et al. compared three-dimensional power Doppler with
gray-scaleandcolorDopplerultrasonographyfordiagnosing
placenta accreta. Three-dimensional power Doppler was
targeted to detect angioarchitecture in the basal and lateral
views of the placenta. The ultrasound ﬁndings were analyzed
with reference to the ﬁnal diagnosis made during Cesarean
delivery. The authors observed that “numerous coherent
vessels” detected by three-dimensional power Doppler in the
basal view were the best single criterion for the diagnosis of
placenta accreta, with a sensitivity of 97% and a speciﬁcity
of 92%. They concluded that three-dimensional power
Doppler may be useful as a complementary technique for the
antenatal diagnosis or exclusion of placenta accreta [33].
If the ultrasound ﬁndings are not considered deﬁnitive,
or the placenta is located on the posterior wall, magnetic
resonance imaging can be performed using gadolinium
contrastintravenously.Magneticresonanceimaging ﬁndings
considered suspicious for the presence of placenta accreta
include placental heterogeneity, mass eﬀect of the placenta
into the underlying bladder or extending laterally or posteri-
orly beyond the normal uterine contour, obliteration of the
myometrial zone visible on initial uptake of gadolinium, and
a beading nodularity within the placenta [34].
Other than the imaging methods, elevated biochemical
markers in maternal serum such as elevated levels of alpha
fetoprotein and human chorionic gonadotropin within the
triple screening test have been reported to be associated with
an increased risk of placenta accreta. Though the mechanism
is unclear, abnormality of the placental-uterine interface that
mayleadtoleakageintothematernalcirculationmayexplain
this increase [35, 36].
Atthistimenoantenataldiagnostictechniqueaﬀordsthe
clinician 100% assurance of either ruling in or ruling out
the presence of placenta accreta. The deﬁnitive diagnosis of
placentaaccretaisusuallymadepostpartumonhysterectomy
specimens when an area of accretion shows chorionic villi in
direct contact with the myometrium and absence of decidua
[26, 37].
5. Management
Women with placenta accreta are usually delivered by a
cesarean section. It is better to perform the surgery under
elective, controlled conditions rather than as an emergency
without adequate preparation. In addition, regardless of
the management option made, prevention of complications
ideally requires a multidisciplinary team approach [9].
The multidisciplinary team should include a gynecologic
surgeon experienced in pelvic surgery, a blood bank team
prepared to administer multiple blood components, experi-
enced anesthesiology personnel who are skilled in obstetric
anesthesia, skilled urologists in case a bladder resection
or repair might be required, experienced intensivists for
postpartum care, and an experienced neonatologist. In cases
where pelvic artery catheterizations are used, an experienced
interventional radiologist is also required. Additionally, Eller
et al. showed that delivery at a medical center with a
multidisciplinary care team resulted in a more than 50%
risk reduction for composite early morbidity among all cases
of placenta accreta and a nearly 80% risk reduction among
those cases wherein accreta was suspected before delivery
[38].
There is a great beneﬁt of planned as opposed to emer-
gent peripartum hysterectomy. In mothers with placenta
previa and a suspected accreta who required peripartum
hysterectomy, a scheduled delivery has been associated with
shorter operative times and lower frequency of transfusions,
complications, and intensive care unit admissions [39].
Accordingly timing of delivery may have a crucial
impact on maternal and perinatal outcome. O’Brien et al.
reported that after 35 weeks, 93% of patients with placenta
accreta experience hemorrhage necessitating delivery [5].
Additionally Warshak et al. reported that planned delivery
at 34 to 35 weeks of gestation in a cohort of 99 cases of
accreta did not signiﬁcantly increase neonatal morbidity
[9]. Robinson and Grobman compared strategies for the
timing of delivery in individuals with placenta previa and
ultrasonographic evidence of placenta accreta to determine
theoptimalgestationalagefordelivery.Thestrategiesranged
from a scheduled delivery at 34, 35, 36, 37, 38, or 39 weeks of
gestation to a scheduled delivery at 36, 37, or 38 weeks of
gestation only after amniocentesis conﬁrmation of fetal lung
maturity. They found that a scheduled delivery at 34 weeks
of gestation was the preferred strategy and that at any given
gestational age, incorporating amniocentesis for veriﬁcation
of fetal lung maturity does not assist in the management of
such individuals [39]. In view of that and in order to avoid
an emergency cesarean on the one hand and to minimize
complications of prematurity on the other, it is acceptable
to schedule cesarean at 34 to 35 weeks.
The best anesthetic method among women with placenta
accreta is controversial. The American Society of Anesthe-
siologists task force on obstetric anesthesia suggested that
general anesthesia may be the most appropriate choice in
some circumstances, including cases where severe hemor-
rhage is anticipated [40]. Chestnut et al. suggested that
epidural anesthesia might be an appropriate choice for
some of these patients. However, the decision to administer
regional anesthesia should be individualized and made only
after review of the pertinent history, physical examination,
and appropriate laboratory/imaging data. Extensive pelvic
invasionand/orsigniﬁcantpotentialformajorintraoperative
bleeding still favors general anesthesia [41].4 Obstetrics and Gynecology International
Regardless of the anesthetic technique used, anesthe-
sia considerations should include insertion of large-bore
venous access to allow rapid crystalloid and blood product
infusion, availability of high ﬂow rate infusion and suc-
tion devices, hemodynamic monitoring capabilities (central
venous and peripheral arterial access), compression stock-
ings and devices to prevent thromboembolism, padding and
positioning to prevent nerve compression, and avoidance
and treatment of hypothermia [31]. Consideration may be
given to the use of the cell saver and acute normovolemic
hemodilution. While both these techniques remain contro-
versial forthe parturient, recent data attest to their safety and
eﬃcacy [42].
Placenta accreta is most likely to aﬀect the urinary
bladder [23]. Placenta accreta that invades the urinary
bladder may cause urinary ﬁstula, ureteral transection, and
bladder laceration requiring partial or total cystectomy [23].
Data suggest that preoperative ureteric stent placement may
help reduce the risk of ureteric injury. Moreover, cystoscopic
placement of ureteric stents can usually be accomplished
quickly and easily even in an emergency and is associated
with relatively minimal risk [43]. If bladder involvement is
suspected, cystotomy may be needed to clarify the extent of
invasion after devascularization of the uterus is achieved and
to ensure ureteric patency if stents were initially not inserted
[31].
The optimal management after delivery of the neonate
is vague. The literature is based on small case reports and
retrospective analysis but lacks prospective trials. Hysterec-
tomy immediately after delivery of the neonate without
attempts at placental removal had been reported to lower
mortality and morbidity rates compared to conservative
management especially in cases of placenta percreta. This
procedure became, and still is, since 1972, the recommended
treatment option [18, 19, 44].
Conservative management, which includes delivery by a
cesarean section without hysterectomy, had been proposed
in selective cases to preserve fertility. The primary idea of
conservative management is to leave the entire placenta
or just the part that is adherent to the myometrium in
situ and to preserve the uterus. Manual removal of densely
adherent placental areas should not be tried because forceful
separation may result in severe bleeding [20, 45]. Kayem
et al. compared maternal outcomes among women with a
placenta accreta, within two consecutive periods: period A,
theplacentawasremovedmanuallyleavingtheuterinecavity
empty; period B, the placenta was left in situ. During period
B, there was a signiﬁcant reduction in the hysterectomy
rate, the mean number of red blood cells transfused, and
in the incidence of disseminated intravascular coagulation
compared with period A [46].
Postoperative complications reported with a conser-
vative approach include severe postpartum hemorrhage,
postoperative disseminated intravascular coagulopathy, and
infection resistant to antimicrobial therapy that may require
laparotomy and hysterectomy [17, 21, 47, 48]. Timmermans
et al. reviewed all articles on conservative management
of abnormally invasive placentation published from 1985
through 2006. During the study period, 48 reports described
outcomes of 60 women who were treated conservatively
for abnormally invasive placentation. Preserving the uterus
succeededinabout80%ofthewomenwithsubsequentpreg-
nancies in at least approximately one-sixth of women. Treat-
ment failure due to vaginal bleeding was the most important
complication of conservative management of abnormally
invasive placentation requiring prolonged follow-up. The
authors concluded that conservative management of abnor-
mally invasive placentation can be eﬀective and fertility can
bepreserved.However,itshouldonlybeconsideredinhighly
selectedcaseswhenbloodlossisminimalandthereisadesire
for fertility preservation [21].
Another retrospective, multicenter study of conservative
management of placenta accreta reported the outcome of
167 women treated in 25 French university hospitals. The
authorsshowedthatincenterswithadequateequipmentand
resources, conservative treatment for placenta accreta is a
valuable option with a success rate of 78.4% and a severe
maternal morbidity rate of 6.0%. However, conservative
treatment required women adherence to treatment over a
long postpartum period, which suggests that women may
continue to be at risk for severe morbidity and possibly
mortality for weeks or even months after delivery. In
view of that and until randomized trials are performed,
the authors suggested that cesarean hysterectomy without
attempt of placental removal should be strongly considered
for placenta accreta in multiparous women not interested in
preserving their fertility according to the authors [49]. In a
subsequent study, the same group described the fertility and
pregnancy outcomes after successful conservative treatment
for placenta accreta, that is, uterine preservation. Of all 96
women available for follow-up 8.3% had severe intrauterine
synechiae and were amenorrheic. Of the 27 women who
desired more children, 88.9% had had 34 pregnancies that
resulted in 21 deliveries of healthy babies born after 34 weeks
of gestation. The mean time to conception was 17.3 months.
Placenta accreta recurred in 28.6% of cases [50].
In spite of the described outcomes, it is worth to mention
thelimitationsofreviewofcasereportsthatoccasionallymay
represent a publication bias. Lethal and other severe com-
plications of conservative management of placenta accreta
may be scarcely reported and prone to being underreported
while good outcomes may be overreported. Additionally, the
wide variety of management techniques makes it hazardous
to draw strong conclusions on eﬀectiveness.
The role of adjuvant methotrexate in cases of conserva-
tive management is uncertain. No large studies have com-
pared methotrexate with no methotrexate in the treatment
of placenta accreta, and at the present time, there are no
convincing data for or against the use of Methotrexate in
cases of placenta accreta [21].
Recently, inserting intravascular balloon catheter for
occlusion and/or arterial embolization of the pelvic arteries
was introduced as an invasive adjuvant therapy in order
to minimize blood loss during cesarean hysterectomy. In
selective cases the placement of a balloon catheter was
done concurrently with conservative management with the
intent of avoiding hysterectomy, thereby preserving fertility
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performed at various sites from as proximal as the aorta [52]
to more distally within the anterior division of the internal
iliac arteries [53]. More often than not, this technique has
been combined with concomitant arterial embolization. The
rational of inserting intravascular balloon catheters is to
decrease blood ﬂow to the uterus and potentially lead to
reduced blood loss. In addition it makes possible to perform
surgery under easier, more controlled circumstances, with
less profuse hemorrhage. Thus far, the results of using
preoperative prophylactic internal iliac artery catheterization
as an adjuvant treatment to hysterectomy or in cases of
conservative management are equivocal and are largely
limited by the small sample size. Though several studies
have shown that preoperative prophylactic artery catheteri-
zation may reduce intraoperative blood loss and transfusion
requirements in patients with placenta accreta or may assist
in preserving fertility [1, 14, 53–55], others did not show
that its use was beneﬁcial for women with placenta accreta.
Additionally the procedure is not without harm and may be
accompanied with other vascular complications [21, 56–58].
Shrivastava et al. suggested that failure of intravascular
balloon catheters to reduce blood loss may be explained by
the extensive degree of uterine blood ﬂow with pregnancy
and the extensive vascular anastomoses present in the gravid
pelvis. In addition, whereas reduction of blood ﬂow to the
uterine arteries likely occurs following balloon inﬂation in
the hypogastric arteries, collateral circulation from cervical,
ovarian, rectal, femoral, lumbar, and sacral arteries likely
contribute to the overall blood loss. Inﬂation of the balloons
immediately following delivery of the infant may actually
exacerbate collateral blood ﬂow [57].
6. Conclusion
Placenta accreta is becoming an increasingly common com-
plication of pregnancy. Prenatal diagnosis seems to be a key
factor in optimizing the counseling, treatment, and outcome
of women with placenta accreta. Cesarean hysterectomy is
probably the preferable treatment.
Conservative management should only be used in highly
selected cases. Even though there may be a rationale to add
adjuvant therapy in such cases, there is no evidence-based
proof that such therapy is actually of beneﬁt or that it is not
in fact harmful.
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